Cell and Tissue Banking

, Volume 8, Issue 4, pp 303–305

Evaluation of tissue discards after implementation of anti-HBc test in a tissue bank in Spain

  • Rafael Villalba
  • Gema Fornés
  • Marcela Eisman
  • Jose Luis Gómez Villagrán
Brief Communication

Abstract

The recent introduction as a minimum test required in The Guide to Safety and Quality Assurance for Organs, Tissues and Cells (Council Europe) and the Directive 2004/23/EC applied to donation, procurement, testing, processing, preservation, storage and distribution of human cells and tissues make necessary the implementation of these markers in all European Tissue Establishments. In this study we have analyzed the impact in tissues discard by introducing anti-HBc in a European Tissue Establishment in a country with a high prevalence of HBV infection. The adoption of this exclusion criteria in this region results in acceptably rejection rates among tissue donors, although some studies are needed on basis a risk assessment to determine the eligibility for clinical use.

Keywords

Hepatitis B Tissue transplantation Safety Testing 

Abbreviations

HBV

Hepatitis B virus

HCV

Hepatitis C virus

HIV

Human immunodeficiency virus

HBs Ag

Hepatitis B surface antigen

HBc

Hepatitis B core

NAT

Nucleic acid test

References

  1. Allain JP (2004) Occult hepatitis B virus infection: implications in transfusion. Vox Sanguinis 86:83–91PubMedCrossRefGoogle Scholar
  2. Allain JP, Reesink HW, Lucey C (2006) A European perspective on the management of donors and units testing positive for hepatitis B virus DNA. Transfusion 46:1256–1258PubMedCrossRefGoogle Scholar
  3. Alvarez M, Oyonarte S, Rodriguez PM, Hernández JM (2002) Estimated risk of transfusion-transmitted viral infections in Spain. Transfusion 42:994–998PubMedCrossRefGoogle Scholar
  4. Colomina J, González D, Burgos A, Fernández N, Guerrero A (2005) Significado de la reactividad aislada anti-HBc como único marcador de infección de la hepatitis B. Enf Infecc Microbiol Clin 23:80–85CrossRefGoogle Scholar
  5. Kleinman SH, Busch MP (2001). HBV: amplified and back in the blood safety spotlight. Transfusion 41:1081–1085PubMedCrossRefGoogle Scholar
  6. Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP (2004) Lack of correlation between HBs Ag and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Transfusion 44:1332–1339PubMedCrossRefGoogle Scholar
  7. Roth WK, Weber M, Petersen D, Drosten C, Buhr S, Sireis W, Weichert W, Hedges D, Seifried E (2002) NAT for HBV and anti-HBc testing increase blood safety. Transfusion 42:869–875PubMedCrossRefGoogle Scholar
  8. Strong DM, Nelson K, Pierce M, Stramer SL (2005) Preventing disease transmission by deceased tissue donors by testing blood for viral nucleic acid. Cell Tissue Bank 6:255–262PubMedCrossRefGoogle Scholar
  9. Zervou EK, Dalekos GN, Boumba DS, Tsianos EV (2001) Value of anti-HBc screening of blood donors for prevention of HBV infection: results of a 3-year prospective study in nortwestern Greece. Transfusion 41:652–658PubMedCrossRefGoogle Scholar
  10. Zou S, Dodd RY, Stramer SL, Strong DM (2004) Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. N Engl J Med 351:751–759PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2007

Authors and Affiliations

  • Rafael Villalba
    • 1
  • Gema Fornés
    • 1
  • Marcela Eisman
    • 1
  • Jose Luis Gómez Villagrán
    • 1
  1. 1.Centro Regional de Transfusión Sanguínea y Banco Sectorial de TejidosCordobaSpain

Personalised recommendations